DISCOVER
A PATH

TO ASTHMA
CONTROL

99.9% of insurance
plans require no biomarker
testing for OCS-dependent
asthma patients4

VIEW COVERAGE DATA


Identify the range of
patients appropriate
for DUPIXENT

BUILD A PATIENT

DUPIXENT is a dual inhibitor of IL-4 and IL-13 signaling and is not an immunosuppressant2

EXPLORE THE MOA
The mechanism of dupilumab action in asthma has not been established.
NOW AVAILABLE

The DUPIXENT 300 mg Pre-filled Pen is now available for appropriate patients aged 12+ years!

SEE DOSING OPTIONS
  • a With DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (Trial 1, secondary endpoint).
  • b At Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in patients with baseline blood eosinophils ≥300 cells/μL (Trial 2, secondary endpoint).
  • c At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (Trial 3, primary endpoint).
  • OCS, oral corticosteroid; SOC, standard of care.

References:

  1. Data on file, Sanofi US. IQVIA Patient Insights; data through March 2020.
  2. DUPIXENT Prescribing Information.
  3. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.